Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1177/00099228221075915 | DOI Listing |
Curr Oncol
November 2024
School of Kinesiology, Yeungnam University, 280, Daehak-ro, Gyeongsan 38541, Gyeongbuk, Republic of Korea.
Colorectal cancer (CRC) is the third most common cancer globally. Therefore, this study aims to examine data from the National Health Insurance Sharing Service (NHISS) to investigate factors influencing colon cancer incidence, focusing on key variables and optimal cutoff points. The patient cohort from the NHISS database included 1,120,377 individuals aged 1-85 years.
View Article and Find Full Text PDFClin Transl Sci
January 2025
Department of Pharmacy, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Mycophenolic acid (MPA) is commonly used to treat autoimmune diseases in children, and therapeutic drug monitoring is recommended to ensure adequate drug exposure. However, multiple blood sampling is required to calculate the area under the plasma concentration-time curve (AUC), causing patient discomfort and waste of human and financial resources. This study aims to use machine learning and deep learning algorithms to develop a prediction model of MPA exposure for pediatric autoimmune diseases with optimizing sampling frequency.
View Article and Find Full Text PDFAnn Child Neurol Soc
June 2024
Division of Neurology, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
Objective: Tuberous sclerosis complex (TSC) results from overactivity of the mechanistic target of rapamycin (mTOR). Sirolimus and everolimus are mTOR inhibitors that treat most facets of TSC but are understudied in infants. We sought to understand the safety and potential efficacy of preventative sirolimus in infants with TSC.
View Article and Find Full Text PDFPediatr Res
December 2024
Department of Neurological Surgery, Ohio State University Medical Center, Columbus, OH, USA.
Background: Post-hemorrhagic hydrocephalus (PHH) is a severe complication in premature infants following intraventricular hemorrhage (IVH). It is characterized by abnormal cerebrospinal fluid (CSF) accumulation, disrupted CSF dynamics, and elevated intracranial pressure (ICP), leading to significant neurological impairments.
Objective: This review provides an overview of recent molecular insights into the pathophysiology of PHH and evaluates emerging therapeutic approaches aimed at addressing its underlying mechanisms.
BMJ Open
December 2024
Department of Paediatrics, Nara Medical University, Kashihara, Japan.
Introduction: Emicizumab prophylaxis is approved for people of all ages with haemophilia A (HA) including infants and children. Although previous studies have demonstrated the efficacy and tolerability of emicizumab in infants with HA, real-world data on emicizumab use in infants are limited. The Haemophilia A in Infancy and NewbOrns: multi-instituional prospective observational study to assess the efficacy anD safety of Emicizumab (HINODE) study aims to evaluate the coagulation potential and safety of emicizumab prophylaxis in infants with congenital HA from birth to <12 months of age.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!